While EZH2 inhibitors like tazemetostat have shown promise in clinical trials, their effectiveness in GBM remains inconsistent, since prolonged inhibition of EZH2 in GBM cells has been linked to tumor progression due to activation of cell proliferation and DNA damage repair pathways. Here, EZH2 is linked to glioblastoma.